NCT04903873View on ClinicalTrials.gov

A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

110

Participants

Timeline

Start Date

May 31, 2021

Primary Completion Date

September 30, 2025

Study Completion Date

December 31, 2025

Conditions
Solid TumorRenal Cell Cancer MetastaticNon-Small Cell Lung CancerRenal Cell CarcinomaProstate Cancer
Interventions
DRUG

EU101

EU101 will be administered via intravenous infusion.

Trial Locations (6)

19111

RECRUITING

Fox Chase Cancer Center, Philadelphia

75230

RECRUITING

Mary Crowley Center, Dallas

Unknown

NOT_YET_RECRUITING

National Cancer Center, Ilsan

RECRUITING

Samsung Seoul Hospital, Seoul

RECRUITING

Seoul Asan, Seoul

RECRUITING

Severance Hospital, Seoul

Sponsors

Lead Sponsor

Eutilex
All Listed Sponsors
lead

Eutilex

INDUSTRY